Short Interest of The Day: What Will Happen to Atara Biotherapeutics Incorporated (NASDAQ:ATRA) Next? The Stock Has Decline in Shorts

November 24, 2016 - By Clifton Ray   ·   0 Comments

Short Interest of The Day: What Will Happen to Atara Biotherapeutics Incorporated (NASDAQ:ATRA) Next? The Stock Has Decline in Shorts

The stock of Atara Biotherapeutics Incorporated (NASDAQ:ATRA) registered a decrease of 3.74% in short interest. ATRA’s total short interest was 3.29 million shares in November as published by FINRA. Its down 3.74% from 3.42M shares, reported previously. With 167,100 shares average volume, it will take short sellers 20 days to cover their ATRA’s short positions. The short interest to Atara Biotherapeutics Incorporated’s float is 25.64%. The stock increased 6.28% or $1.15 on November 23, hitting $19.45. About 196,158 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 6.80% since April 22, 2016 and is downtrending. It has underperformed by 12.21% the S&P500.

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $552.29 million. The Company’s segment is the business of developing and commercializing therapeutics. It currently has negative earnings. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Insitutional Activity: The institutional sentiment decreased to 1.48 in Q2 2016. Its down 1.88, from 3.36 in 2016Q1. The ratio dived, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Ladenburg Thalmann Services has 0% invested in the company for 22 shares. The New York-based Metropolitan Life has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Blackrock Inc last reported 0% of its portfolio in the stock. Moreover, Cormorant Asset Management Limited Liability Corp has 0.6% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 186,460 shares. The Georgia-based Vident Investment Advisory Limited Company has invested 0.1% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Goldman Sachs Grp Inc last reported 0% of its portfolio in the stock. Legal General Grp Public Ltd Co holds 3,583 shares or 0% of its portfolio. Proshare Advsr Ltd Liability last reported 0.01% of its portfolio in the stock. Swiss State Bank last reported 26,100 shares in the company. Manufacturers Life Company The last reported 0% of its portfolio in the stock. Bnp Paribas Arbitrage Sa, a New York-based fund reported 937 shares. Moreover, Rtw Invs has 3.58% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 465,874 shares. Great West Life Assurance Com Can accumulated 1,654 shares or 0% of the stock. Blackrock Ltd Liability Company last reported 94,203 shares in the company. Royal Retail Bank Of Canada holds 773 shares or 0% of its portfolio.

Insider Transactions: Since May 25, 2016, the stock had 0 buys, and 18 selling transactions for $2.36 million net activity. $27,247 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by Soffer Gad on Thursday, November 17. $32,000 worth of shares were sold by Haqq Christopher on Tuesday, November 15. Ciechanover Isaac E. also sold $212,208 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Wednesday, July 20. Clark Mitchall G. sold $58,492 worth of stock or 2,995 shares. Shares for $22,910 were sold by Gallagher Carol Giltner on Tuesday, November 15. MCGRATH JOHN had sold 5,000 shares worth $87,325.

Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage

Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock has “Sell” rating given by Citigroup on Tuesday, December 15. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Sell” rating given on Friday, August 19 by Citigroup. On Monday, August 22 the stock rating was maintained by Citigroup with “Sell”. On Friday, October 9 the stock rating was initiated by William Blair with “Outperform”. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, November 18 report. Canaccord Genuity initiated it with “Buy” rating and $80 target price in Wednesday, September 9 report. The rating was downgraded by Goldman Sachs to “Sell” on Thursday, September 15. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Market Outperform” rating given on Tuesday, December 15 by JMP Securities. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Mkt Perform” rating given on Friday, September 25 by JMP Securities.

ATRA Company Profile

Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.

More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Fool.com which released: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Also Marketwatch.com published the news titled: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>